» Authors » Esli Medina-Morales

Esli Medina-Morales

Explore the profile of Esli Medina-Morales including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 100
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Amaris N, Marenco-Flores A, Barba R, Rubio-Cruz D, Medina-Morales E, Goyes D, et al.
J Clin Med . 2024 Nov; 13(22). PMID: 39597786
: Acute liver failure (ALF) involves rapid liver injury, often leading to multi-organ failure. Liver transplantation (LT) has improved survival rates, with U.S. rates reaching 92%. This study analyzes UNOS...
2.
Medina-Morales E, Ismail M, Goyal R, Marenco-Flores A, Saberi B, Fricker Z, et al.
Liver Int . 2024 Sep; 44(11):3083-3095. PMID: 39258855
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), in the context of autoimmune hepatitis (AIH) among liver transplantation (LT) candidates or recipients remains poorly understood. This study compares waitlist...
3.
Marenco-Flores A, Amaris N, Kahan T, Sierra L, Barba Bernal R, Medina-Morales E, et al.
J Clin Med . 2024 Aug; 13(15). PMID: 39124763
The cornerstone treatment for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA), but many patients exhibit an incomplete response, leading to disease progression. Risk prediction models like the GLOBE and...
4.
Lam L, Soret P, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, et al.
Clin Gastroenterol Hepatol . 2024 Jul; 22(12):2432-2441.e2. PMID: 39019421
Background & Aims: In primary biliary cholangitis (PBC), static liver stiffness measurement (LSM) has proven prognostic value. However, the added prognostic value of LSM time course in this disease remains...
5.
Abboud Y, Ismail M, Khan H, Medina-Morales E, Alsakarneh S, Jaber F, et al.
J Clin Transl Hepatol . 2024 Feb; 12(2):172-181. PMID: 38343612
Background And Aims: While the incidence rates of hepatocellular carcinoma (HCC) are increasing, there are limited comprehensive data on demographic-specific incidence and mortality trends in the USA. We aimed to...
6.
Sierra L, Marenco-Flores A, Barba R, Goyes D, Ferrigno B, Diaz W, et al.
Ann Hepatol . 2023 Dec; 29(3):101283. PMID: 38151060
Introduction And Objectives: Autoimmune liver diseases (AILDs): autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) have different survival outcomes after liver transplant (LT). Outcomes are influenced...
7.
Abboud Y, Mathew A, Aghaie Meybodi M, Medina-Morales E, Alsakarneh S, Choi C, et al.
Clin Gastroenterol Hepatol . 2023 Nov; 22(4):798-809.e28. PMID: 38036281
Background & Aims: Previous studies show that mortality from chronic liver disease (CLD) and cirrhosis is increasing in the United States. However, there are limited data on sex-specific mortality trends...
8.
Medina-Morales E, Ismail M, Barba Bernal R, Abboud Y, Sierra L, Marenco-Flores A, et al.
J Clin Med . 2023 Oct; 12(20). PMID: 37892674
Primary biliary cholangitis (PBC) prompts liver transplantation (LT) due to cholestasis, cirrhosis, and liver failure. Despite lower MELD scores, recent studies highlight higher PBC waitlist mortality, intensifying the need for...
9.
Corpechot C, Lemoinne S, Soret P, Hansen B, Hirschfield G, Gulamhusein A, et al.
Hepatology . 2023 Jul; 79(1):39-48. PMID: 37399238
Background And Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended...
10.
Medina-Morales E, Barba Bernal R, Gerger H, Goyes D, Trivedi H, Ferrigno B, et al.
J Clin Gastroenterol . 2023 Jan; 57(2):143-152. PMID: 36598806
Goals: We aim to summarize the current management of pruritus in primary biliary cholangitis (PBC) by evaluating the efficacy and safety of pharmacological therapies. Background: Pruritus is a common symptom...